Jump to content

Talk:Jeffrey Leiden

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

Edit request to update the Vertex section

[edit]

Hi. I am John and I would like to request some updates to Jeffrey Leiden's article.

  • Please add the following sentence as a new paragraph in the correct chronological order in the Vertex section, after the sentence that begins "In 2015 Vertex shareholders..." "The 2019 acquisition of Semma Therapeutics led to VX-880, the first potentially curative stem cell-based therapy for patients with type 1 diabetes.[1][2]
  • At the end of the sentence that begins "On October 24, 2019, Vertex reached..." please remove Scotland and Spain and replace with Ireland[3] and [[France][4], among others.
  • Also in the Vertex section, please add the following as a new paragraph below the sentence that begins "On October 24, 2019, Vertex reached an agreement..." "While Leiden served as chairman, the market capitalization of Vertex Pharmaceuticals increased from $7.74 billion at the beginning of 2012 to $69.97 billion in April 2020.[5][6]
  • In the last paragraph of the Vertex section, please change April 2023 to April 2024.[7]

References

  1. ^ Gelman, Max (29 January 2021). "The diabetes 'cure' Vertex acquired in its 2019 Semma buyout? It's headed to the clinic". Endpoints News.
  2. ^ Bell, Jacob (10 March 2021). "Vertex begins human testing for diabetes cell therapy". BiopharmaDive.
  3. ^ "Landmark NHS deal to open up access to life-changing cystic fibrosis drug". EnglandNHS. 21 August 2020.
  4. ^ Bruce, Francesca (15 July 2021). "Vertex Inks New Cystic Fibrosis Deals In Europe". Pink Sheet.
  5. ^ "VRTX Market Cap History". Market Cap History. 31 January 2022.
  6. ^ "Market capitalization of Vertex Pharmaceuticals (VRTX)". Companies Market Cap. 31 March 2022.
  7. ^ "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Form 10-K". investors.vrtx.com. SEC.

Thank you for your help, JohnDatVertex (talk) 17:43, 1 April 2022 (UTC)[reply]

checkY Partially done, as the sources provided for #1 said no such thing, and I'm not sure about the reliability of #2's. PK650 (talk) 07:45, 3 April 2022 (UTC)[reply]
I am marking this request as answered, per the above. Z1720 (talk) 14:36, 5 April 2022 (UTC)[reply]
Hi PK650. Thanks for helping out with the above edits. I have re-written the sentence for the first edit that you declined above in a way that more precisely reflects the sources supplied. Please add the following as a new paragraph after the sentence that begins "In 2015 Vertex shareholders..." "Also under his leadership, Vertex acquired Semma Therapeutics for $950 million in 2019. The company developed stem cell-derived therapies including the experimental cell therapy for Type 1 diabetes known as VX-880. [1][2]"

References

  1. ^ Gelman, Max (29 January 2021). "The diabetes 'cure' Vertex acquired in its 2019 Semma buyout? It's headed to the clinic". Endpoints News.
  2. ^ Bell, Jacob (10 March 2021). "Vertex begins human testing for diabetes cell therapy". BiopharmaDive.
Thanks so much. JohnDatVertex (talk) 13:10, 16 May 2022 (UTC)[reply]

Addition to Boards section

[edit]

Hi. This is John again. Please update the Boards and awards section with the following sentence: In May 2022 Leiden joined the Board of Directors of Odyssey Therapeutics. [1]

References

  1. ^ "About: Our Leadership". Odyssey Therapeutics.
 Done

I am pinging PK650 who has helped on this page in the past. Thanks so much. JohnDatVertex (talk) 15:17, 19 May 2022 (UTC)[reply]

Remove Tmunity, an outdated board post

[edit]

Hello. Please remove the mention of Tmunity in the second paragraph of the Boards and awards section. Leiden no longer sits on that board. This link shows he is no longer on the board of Tmunity I am pinging Iztwoz who helped with my last edit request. Thanks so much. JohnDatVertex (talk) 12:32, 13 June 2022 (UTC)[reply]

Additional board position and thanks

[edit]

Thanks Iztwoz for implementing my edit request. I have an additional board membership to be added to the "Boards and awards" section as follows: "Leiden is a member of the MIT Presidential CEO Advisory Board." The source is https://www.dropbox.com/s/6nfjmjqb98o9p4k/2022%20MIT%20CEO%20AB%20BRIEFING.pdf?dl=0 on page 21.

I would also appreciate if you could take a look at Talk:Reshma Kewalramani and implement those simple, straightforward edits that are requested there. Thanks again. JohnDatVertex (talk) 13:24, 21 June 2022 (UTC)[reply]

The board membership was resolved below. -Kj cheetham (talk) 17:34, 7 September 2022 (UTC)[reply]

Board position and Semma acquisition

[edit]

I have two edits to request, as follows:

  • Please add the following sentence to the end of the 'Boards and awards' section:
Leiden is a member of the MIT Presidential CEO Advisory Board.[1]
  • Please add the following as a new paragraph after the sentence that begins "In 2015 Vertex shareholders..."
Also under his leadership, Vertex acquired Semma Therapeutics for $950 million in 2019. The company developed stem cell-derived therapies including the experimental cell therapy for Type 1 diabetes known as VX-880.[2][3]

References

  1. ^ "MIT Presidential Advisory Board Annual Meeting" (PDF). MIT. 23 June 2022.
  2. ^ Gelman, Max (29 January 2021). "The diabetes 'cure' Vertex acquired in its 2019 Semma buyout? It's headed to the clinic". Endpoints News.
  3. ^ Bell, Jacob (10 March 2021). "Vertex begins human testing for diabetes cell therapy". BiopharmaDive.

I am pinging Kj cheetham who was helpful with edits for Reshma Kewalramani recently. Thanks so much. JohnDatVertex (talk) 13:39, 31 August 2022 (UTC)[reply]

Hi JohnDatVertex, I've implemented your 2nd point, but do you have a better source for the first point? I'm hestitant to link to something on dropbox. Thanks. -Kj cheetham (talk) 15:21, 1 September 2022 (UTC) P.S. https://www.vrtx.com/our-company/leadership/jeffrey-leiden/ might be sufficient though? -Kj cheetham (talk) 15:29, 1 September 2022 (UTC)[reply]
Hi Kj cheetham. Thanks for implementing the second bullet point above. Sorry that the source for the first bullet point caused you to hesitate about using something on dropbox. I am happy for you to use the Vertex website if you feel that is a better option. Once again, thank you for your work. JohnDatVertex (talk) 17:29, 7 September 2022 (UTC)[reply]
JohnDatVertex  Done -Kj cheetham (talk) 17:33, 7 September 2022 (UTC)[reply]
Thanks Kj cheetham for your fast and helpful edit. JohnDatVertex (talk) 12:41, 9 September 2022 (UTC)[reply]

Odyssey Therapeutics and market value increase

[edit]

Thanks again Kj_cheetham for your recent help with this page. I hope you can take a look at the following edits and implement them if you agree they add value to the page.

  • For clarity and accuracy, please change the sentence "In May 2022 Leiden joined the Board of Directors of Odyssey Therapeutics" in the "Boards and awards" section to the following:
In May 2022 Leiden was appointed as Chairman of the Board of Odyssey Therapeutics, a company developing novel medicines for cancer and auto-immune disease.[1]
  • Please move the above sentence about Odyssey to the end of the first paragraph in the "Boards and awards" section, directly after "Leiden is also the chairman of Casana, a home health monitoring company. The sentence fits better there since Leiden is the chairman of those boards mentioned in that paragraph.
  • Please add the following as a new paragraph in the "Vertex" section below the sentence that begins "On October 24, 2019, Vertex reached an agreement..."
While Leiden served as chairman, the market capitalization of Vertex Pharmaceuticals increased from $7.74 billion at the beginning of 2012 to $69.97 billion in April 2020.[2]

References

  1. ^ "Odyssey Therapeutics:News". odysseytx.com/news. 24 May 2022.
  2. ^ Doler, Kathleen (16 July 2020). "How A Medical Brainiac CEO Turned Brilliance Into Billions".

Thanks so much. JohnDatVertex (talk) 18:27, 20 September 2022 (UTC)[reply]

 Done The only thing I've done different is rather than a new paragraph I've added the sentance to the end of an existing one, just to try and avoid too many very short paragraphs. Kj cheetham (talk) 11:19, 2 October 2022 (UTC)[reply]

JP Morgan advisor and Boston Bus Journal years

[edit]

Once again, I want to express my appreciation to Kj_cheetham for implementing my most recent edit request. Below are a few additional requests:

  • Please add the following sentence to the end of the 'Boards and awards' section:
In November 2022 Leiden was named as one of several strategic advisors for the newly launched Life Sciences Private Capital, a private equity division of J.P. Morgan.[1]
  • In the third paragraph of the 'Boards and awards' section please replace this sentence:
Leiden was also named one of Boston Business Journal’s Power 50 in 2018.

With this sentence instead:

Leiden was also named one of Boston Business Journal’s Power 50 for several years, including most recently in 2022.[2]

References

  1. ^ Bayer, Max (3 November 2022). "J.P. Morgan's new life sciences private equity arm will be hottest ticket at firm's upcoming conference". Fierce Biotech.
  2. ^ "Meet the 2022 Boston Business Journal Power 50 Movement Makers". Boston Business Journal. 16 November 2022.

Thanks again for all your help. JohnDatVertex (talk) 14:52, 28 November 2022 (UTC)[reply]

Hi Kj cheetham. This is a gentle nudge in the hope that you have the time to make the simple edits as outlined above. Thanks again for all your past and future help. JohnDatVertex (talk) 13:58, 5 December 2022 (UTC)[reply]
 Done Kj cheetham (talk) 12:06, 8 December 2022 (UTC)[reply]
Thanks again Kj cheetham for all your help. JohnDatVertex (talk) 15:21, 15 December 2022 (UTC)[reply]

MACP board membership

[edit]

Hi again. The Boards and awards section needs another update. Please change the sentence "He is also chairman of the board of the Massachusetts Competitive Partnership" to the following:

He is a director of the Massachusetts Competitive Partnership (MACP) and previously served as chair from January 2020 to December 2022.[1][2]

References

  1. ^ "MACP". masscompetes.org.
  2. ^ "Jeffrey Leiden, MD, PhD". Vrtx.com.

Thanks so much for your help in the past, Kj_cheetham. I am hoping you can help out again with this edit request. JohnDatVertex (talk) 15:36, 21 February 2023 (UTC)[reply]

This new information has been added to the awards section and this edit request has been answered. Go4thProsper (talk) 18:40, 4 March 2023 (UTC)[reply]

Vertex section edits

[edit]

Hi. Please remove the following recently added paragraphs from the Vertex section of the Leiden Wikipedia article. The added content violates WP:COATRACK: it has little or nothing to do with Jeffrey Leiden, and adds details that are not relevant for the reader to get a good understanding of Leiden's relationship to Vertex.

Criticism of Vertex pricing structures for Orkambi, a groundbreaking cystic fibrosis drug costing in the region of US$135,000 to US$270,000[23] per patient per year depending on the patient's country, has resulting in campaigns by concerned parent groups addressed to Leiden.[24][25] Leiden wrote to the UK Prime Minister Theresa May in 2018, suggesting Vertex might consider reducing investment in the UK as a result of the lack of agreement between Vertex and the UK's National Health Service on the pricing of a five-year access agreement for Vertex drugs.[26]
However in November 2023 the National Institute for Health and Care Excellence (NICE) recommended that three Vertex drugs, Kaftrio, Orkambi and Symkev were above the acceptable range of NHS resources in terms of cost effectiveness, despite positive outcomes for Cystic Fibrosis patients.[32]

Pinging Kj cheetham who has helped here in the past. Thanks, JohnDatVertex (talk) 14:59, 13 March 2024 (UTC)[reply]

I've declined this because the statements are factually correct and written in neutral tone and relate to actions that Leiden has made. Sky News certainly isn't the best of sources, but you don't seem to be contesting the factors, only their relevance to the page. It provides information about the business approaches that Leiden uses to as a CEO; for example, lobbying the Prime Minister (going over the top of NICE). Klbrain (talk) 20:26, 20 May 2024 (UTC)[reply]

Updates

[edit]

Hello. I made some simple edits on Jeffrey Leiden's page which I believe are not controversial in any way, mostly updating some facts, and I summarized the edits I made in the edit summary box. Let me know if I did something inappropriate. However, the following edits are perhaps less straightforward, so I am requesting them.

  • In the first sentence of the article, please add the words "physician, scientist and" right before the word "businessman" so the sentence reads as follows:
Jeffrey Leiden is an American physician, scientist and businessman who is the executive chairman of Vertex Pharmaceuticals…"

It is clear from the content in the article that Leiden is a physician and scientist and those facts should be included in the introduction.

  • Please add the following sentence to the end of the second paragraph in the "Vertex" section:
Casgevy was approved for use in the UK (November 2023), the United States (January 2024) and Europe, (February 2024.)[1]

This information updates the status of these drugs.

  • Please add the following sentence below the fourth paragraph of the Boards and awards section:
  • Please delete the following sentence from the Boards and awards section. It is outdated and incorrect. He is now a director of the MACP, as it says further down in this section:
He is also chairman of the board of the Massachusetts Competitive Partnership.[58]

References

  1. ^ Barrie, Robert (13 February 2024). "CRISPR gene therapy Casgevy secures approval in Europe". Pharmaceutical Technology.

Thanks so much, JohnDatVertex (talk) 23:12, 5 June 2024 (UTC)[reply]

I have reviewed the sources provided above, and everything checks out. I have therefore updated the article as requested above. Boghog (talk) 19:22, 15 July 2024 (UTC)[reply]
Thank you so much Boghog for implementing the edit request. If its not too much trouble, can you also add the following to the Infobox under the "Board member of" parameter or, if this is better for you, I can do these edits myself directly, just let me know if I have your permission:
  • Massachusetts Competitive Partnership
  • Odyssey Therapeutics
  • Casana
  • MIT Presidential CEO Advisory Board
  • Governor's Task Force on Artificial Intelligence
And also remove "Path AI" from the Infobox, as Leiden is no longer on that board. Thanks again. JohnDatVertex (talk) 17:51, 16 July 2024 (UTC)[reply]
JohnDatVertex. Thanks for your message. I am hesitant to add the additional board memberships listed above, as it seems like resume padding. The current board memberships in the infobox, except for PathAI, are very significant, with Wikipedia articles dedicated to each one. None of the boards you listed have Wikipedia articles. Restricting the list to the most significant boards maintains focus on what is important and prevents the list from becoming too long, which would be a disservice to the reader. I have removed PathAI from the list. Boghog (talk) 20:08, 25 July 2024 (UTC)[reply]
Hi and thanks again. I understand your reasoning for not adding the additional board memberships. Thanks for explaining it and for the edit you made. All the best. JohnDatVertex (talk) 19:28, 30 July 2024 (UTC)[reply]

Update UK pricing deal

[edit]

Hi again. Due to a deal being reached recently between the UK's NHS and Vertex, the following update to the page should be made:

  • In the section called "Vertex" please change the fifth paragraph by deleting the first part of the last sentence: However in November 2023 the National Institute for Health and Care Excellence (NICE) recommended that three Vertex drugs, Kaftrio, Orkambi and Symkev were and replacing it with
On June 20, 2024, the National Institute for Health and Care Excellence, (NICE) said in its final draft guidance that Orkambi, Symkevi, and Kaftrio are recommended for the treatment of Cystic Fibrosis, with Vertex coming to a long-term, extended, reimbursement agreement[1] with the NHS.[2][3][4] This final decision differs from its provisional draft guidance from November 2023 that recommended that the three drugs were

References

  1. ^ Manalac, Tristan (21 June 2024). "Vertex Finally Reaches Pricing Deal With England's NHS for Cystic Fibrosis Drugs". BioSpace.
  2. ^ Furlong, Ashleigh (20 June 2024). "Vertex Reaches Pricing Deal With NHS for Cystic Fibrosis Drugs". Bloomberg.
  3. ^ Silverman, Ed (20 June 2024). "Vertex reaches a new deal with NHS England over its pricey cystic fibrosis treatments". STAT.
  4. ^ Inácio, Patricia (26 June 2024). "3 CFTR modulators guaranteed public reimbursement in England". Cystic Fibrosis News Today.

Pinging Boghog who helped with the previous edit request. Thanks so much. JohnDatVertex (talk) 13:11, 20 August 2024 (UTC)[reply]

 Done The sources check out, so I have incorporated the above requested changes in this edit. However I am wondering if the fourth and fifth paragraphs of the Jeffrey_Leiden#Vertex section would be better placed in Vertex_Pharmaceuticals#Pricing_in_the_UK section. Boghog (talk) 15:19, 20 August 2024 (UTC)[reply]
Thanks so much Boghog for your edits. I hear your suggestion to move those two paragraphs and I'd appreciate holding off on that for a bit while I am working now on updates to the "Pricing in the UK" section of the Vertex article. When that edit request is ready, I will post it and ping you. I'd appreciate your collaboration and thoughts on those upcoming suggestions. Thanks again. JohnDatVertex (talk) 12:35, 28 August 2024 (UTC)[reply]
Retrieved from "https://wiki.riteme.site/w/index.php?title=Talk:Jeffrey_Leiden&oldid=1242733018"